Compounds and Compositions for the Treatment of Cancer

A method for treating cancer, wherein said method comprises administering, to a subject in need of such treatment, a compound represented by Formula I, or a pharmaceutically acceptable salt thereof:

• Cy-Q Formula I
• wherein:
• Cy is R2, or q
• wherein
• →represents a covalent bond connecting Cy to Q;
• q is 1, 2, or 3;
• A is
• 1) C1-C8 alkyl,
• 2) C2-C6 alkenyl,
• 3) C1-C7 alkyl-Y—,
• 4) C1-C7 alkyl-OC(O)—,
• 5) phenyl-O-phenyl-CH2—Y, or
• 6) C1-C7 alkyl-CH(OH)—;
• R1, R2 and R3 are independently selected from H, F, Cl, and OH;
• when Cy is Cy1 or Cy2, then Q is
• 1) C(O)OH,
• 2) C(CH3)2C(O)OH,
• 3) (CH2)m—C(O)OH,
• 4) ZCH(C(O)OH)C1-C8 alkyl,
• 5) Z(CH2)mC(O)OH,
• 6) CH(Rc)C(O)OH,
• 7) CH(phenyl)CH2C(O)OH,
• 8) CH(Rc)CH2C(O)OH, or
• 9) CH2CH(C(O)OH)C1-C8 alkyl,
• wherein:
• m is 1 or 2;
• the phenyl is substituted by an Rd substituent;
• Y is O, S, NH, NC1-C3 alkyl or C(O);
• Z is O, S, NH or NC1-C3 alkyl;
• when Cy is Cy3, then Q is C(O)OH;
• Rc is
• 1) H,
• 2) C1-C4 alkyl,
• 3) C2-C4 alkenyl, or
• 4) C2-C4 alkynyl;
• Rd is
• 1) ORe,
• 2) halogen,
• 3) CF3, or
• 4) phenyl;
• and
• Re is
• 1) H, or
• 2) C1-C4 alkyl.

A pharmaceutical composition comprising a compound represented by

• Cy-Q Formula I
• wherein:
• Cy is
• wherein
• →represents a covalent bond connecting Cy to Q;
• q is 1, 2, or 3;
• A is
• 1) C1-C8 alkyl,
• 2) C2-C6 alkenyl,
• 3) C1-C7 alkyl-Y—,
• 4) C1-C7 alkyl-OC(O)—,
• 5) phenyl-O-phenyl-CH2—Y, or
• 6) C1-C7 alkyl-CH(OH)—;
• R1, R2 and R3 are independently selected from H, F, Cl, and OH;
• when Cy is Cy1 or Cy2, then Q is
• 1) C(O)OH,
• 2) C(CH3)2C(O)OH,
• 3) (CH2)m—C(O)OH,
• 4) ZCH(C(O)OH)C1-C8 alkyl,
• 5) Z(CH2)mC(O)OH,
• 6) CH(Rc)C(O)OH,
• 7) CH(phenyl)CH2C(O)OH,
• 8) CH(Rc)CH2C(O)OH, or
• 9) CH2CH(C(O)OH)C1-C8 alkyl,
• wherein:
• m is 1 or 2;
• the phenyl is substituted by an Rd substituent;
• Y is O, S, NH, NC1-C3 alkyl or C(O);
• Z is O, S, NH or NC1-C3 alkyl;
• when Cy is Cy3, then Q is C(O)OH;
• Rc is
• 1) H,
• 2) C1-C4 alkyl,
• 3) C2-C4 alkenyl, or
• 4) C2-C4 alkynyl;
• Rd is
• 1) ORe,
• 2) halogen,
• 3) CF3, or
• 4) phenyl;
• and
• Re is
• 1) H, or
• 2) C1-C4 alkyl,
• or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.